Invivogen
Menu

Delta Variant - Luciferase-tagged RBD protein

RBD-LuciaV8 (B.1.617.2) Unit size Cat. code Docs Qty Price
Luciferase tagged RBD protein (B.1.617.2 variant)
50 µg
rbd-lucia-v8
+-
$284.00

You may also need : QUANTI-Luc™ | View more associated products

Recombinant RBD fusion protein (B.1.617.2 variant - Indian origin) for ELISA & LIPS

RBD-LuciaV8 (B.1.617.2) (~52 kDa) is a soluble fusion protein composed of the Spike Receptor Binding Domain (RBD) from the SARS-CoV-2 Delta variant (B.1.617.2) fused to a C‑terminal Lucia luciferase tag. RBD-LuciaV8 (B.1.617.2) has been specifically designed to assess the binding affinity of anti-Spike antibodies using either ELISA or LIPS (luciferase immunoprecipitation systems) assays [1-3].

 More details

 

RBD-LuciaV8 fusion protein for ELISA & LIPS
RBD-LuciaV8 (B.1.617.2) fusion protein for ELISA & LIPS

SARS-CoV-2 Spike RBD

RBD-LuciaV8 (B.1.617.2) contains the Spike RBD domain, including the receptor-binding motif (RBM) from the SARS-CoV-2 Delta variant, first reported in India in October 2020 [4]. This variant is classified as a member of Clade 21A/ B.1.617.2 lineage (Nextstrain/Pango lineage classification). It is characterized by the presence of two key mutations within the Spike RBD coding region, which are of concern [4-5].

  • L452R, T478K
 

Learn more about the emerging SARS-CoV-2 variants around the world

 

Applications

Luciferase-tagged RBD proteins are ideal for studying the binding of anti-spike monoclonal antibodies (mAbs) by solid-phase ELISA and/or solution‑phase LIPS assays, as well as anti‑spike polyclonal antibodies in the sera of recovered COVID‑19 patients and/or vaccinees by LIPS [1-3].

  • ELISA: the Lucia luciferase tag provides a larger dynamic range than the commonly used HRP detection.
  • LIPS: for the detection of antibodies, against both linear and conformational epitopes.
 

RBD‑LuciaV8 (B.1.617.2) has been generated by recombinant DNA technology, produced in CHO cells, and purified by IMAC (Immobilized Metal Affinity Chromatography) using a C‑terminal histidine tag. Protein size and purity (>90%) have been validated by SDS‑PAGE and the absence of endotoxin contamination has been confirmed using cellular assays. 

 

References:

1. Burbelo, P.D. et al. 2010. Antibody-profiling technologies for studying humoral responses to infectious agents. Expert Rev Vaccines 9, 567-578.
2. Haljasmagi, L. et al. 2020. LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins. Eur J Immunol 50, 1234-1236.
3. Liang, Y. et al. 2021. A luciferase immunosorbent assay for quantitative detection of IgG antibodies against SARS-CoV-2 nucleoprotein. J Virol Methods 292, 114141.
4. Davis, C. et al. 2021. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. medRxiv doi:10.1101/2021.06.23.21259327.
5. Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. Retrieved 07 July 2021.

Figures

RBD-LuciaV8 (B.1.617.2) for Luciferase-based ELISA
RBD-LuciaV8 (B.1.617.2) for Luciferase-based ELISA

Luciferase-based ELISA using RBD-LuciaV8 (B.1.617.2). Anti-murine IgG F(ab’)2 fragment (2 µg/ml) was coated on an ELISA plate overnight. Anti-CoV2RBD-cas-mIgG2a, Anti-CoV2RBD-imd-mIgG2a, Anti-CoV2RBD-bam-mIgG2a, Anti-CoV2RBD-ete-mIgG2a, or the negative control Anti-βGal-mIgG2a, along with RBD-LuciaV8 (B.1.617.2) (1 µg/ml) were added and incubated for 2 hours at room temperature. After washing (3x times), binding affinity was assessed by measuring the activity of Lucia luciferase in the supernatant using QUANTI-Luc™. Data are shown as a fold change over no antibody.

Luciferase based ELISA
Luciferase based ELISA

The binding capacity of InvivoGen's anti-SARS-CoV2RBD mAbs to a set of Spike variants has been validated using a Lucia luciferase-based ELISA.
Anti-murine IgG F(ab’)2 fragment (2 µg/ml) was coated on an ELISA plate overnight. Anti-CoV2RBD-cas-mIgG2a, Anti-CoV2RBD-imd-mIgG2a, Anti-CoV2RBD-bam-mIgG2a, Anti-CoV2RBD-ete-mIgG2a along with RBD-Lucia proteins (original and V2 to V8; 1 µg/ml) were added and incubated for 2 hours at room temperature. After washing (3x times), binding affinity was assessed by measuring the activity of Lucia luciferase in the supernatant using QUANTI-Luc™. Data are shown as a fold change over no antibody.

Back to the top

Specifications

RBD-LuciaV8 (B.1.617.2)

  • Protein construction: RBD [R319-F541] from the Spike glycoprotein fused to a C-terminal Lucia luciferase reporter
  • Origin: Delta Variant (B.1.617.2 lineage) | Indian origin
  • Sequence Reference: EPI_ISL_2356230
  • Tag: C-terminal 6x Histidine tag
  • Total protein size: 461 amino acids (including the Lucia luciferase)
  • Molecular weight: ~52 kDa (SDS-PAGE)
  • Purification: Immobilized metal affinity chromatography (IMAC)
  • Purity: >90% (SDS-PAGE)
  • Quality control:
    - The protein has been validated by ELISA upon incubation with a coated Anti-murine IgG (Fab')2 and a clinically relevant anti-Spike mAb.
    - The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.
Back to the top

Contents

RBD-LuciaV8 (B.1.617.2) contents:

  • 50 μg of lyophilized protein
  • 1.5 ml of endotoxin-free water
  • 1 pouch of QUANTI-Luc™

room temperature The product is shipped at room temperature.

store Lyophilized protein should be stored at -20 ̊C.

stability Resuspended protein is stable up to 1 month when stored at 4°C, and 1 year when stored at -20°C

Avoid repeated freeze-thaw cycles.

Back to the top

Details

RBD-Lucia in ELISA

RBD-Lucia proteins can be used in a luciferase-based ELISA. Unlike a conventional ELISA, the plate is coated overnight with an Anti-human IgG F(ab')2 fragment. Upon addition of anti-spike monoclonal antibodies (mAb), they will bind to this 'capture' fragment through their Fc region, and RBD-Lucia will bind to the variable region. The luciferase activity is then used to assess the mAb binding affinity to the Spike RBD.

RBD-Lucia in LIPS

Currently, to perform a LIPS assay, soluble crude cell lysates or culture media of the luciferase tagged recombinant protein are extracted from transfected cells and directly used for the assay. InvivoGen's RBD-Lucia proteins streamline the protocol even further. Simply add the RBD-Lucia protein to either anti-spike mAbs or to anti‑spike polyclonal antibodies in the sera of recovered COVID‑19 patients and/or a vaccinee. Following this, antibody-protein complexes are purified using Protein A beads. Quantification of either binding affinity (mAb) and/or antibody levels (sera) is easily determined by assessing the Lucia luciferase activity.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty